Skip to search formSkip to main contentSkip to account menu

CDISC Trial Design Class

Known as: TRIAL DESIGN 
This SDTM class describes the plan for the procedures to be followed in a clinical trial, including planned and actual timing of events, control… 
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM General Observation Class TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference
Highly Cited
2017
Highly Cited
2017
Pragmatic trials and real world evidence – an introduction to the series
Review
2017
Review
2017
Clinical trials from the patient perspective: survey in an online patient community
BackgroundDeveloping new medicines relies on the successful conduct of clinical trials. As trial protocols become more arduous… 
Review
2017
Review
2017
Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: Systematic review and meta-analysis of placebo-controlled clinical trials
2016
2016
Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group
SummaryWe used the RAND UCLA appropriateness method to decide appropriateness of use of osteoporosis medication after incident… 
Review
2016
Review
2016
Clinical trials for authorized biosimilars in the European Union: a systematic review
Aim In 2006, Omnitrope (by Sandoz) was the first approved biosimilar in Europe. To date, 21 biosimilars for seven different… 
Review
2015
Review
2015
Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design.
Highly Cited
2014
Highly Cited
2014
Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.
Highly Cited
2014
Highly Cited
2014
Patient-centeredness in the design of clinical trials.
Review
2014
Review
2014
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)